Loading stock data…
ERAS
$10.14-0.24 (-2.31%)
Market OpenUpdated 12:50 PM EDT
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Erasca, Inc. in the Healthcare sector is trading at $10.14. Wall Street consensus targets $20.50 (10 analysts), implying a +102.2% move over the next 12 months. The stock is currently 58% below its 52-week high of $24.28, remaining 41.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +102.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 16) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$10.14
Potential Downside
0%
Whystock Fair Value$10.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Buy
Mean target$20.50+102.2%
Range$9.00 – $30.00
Fundamentals
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-38.30%
Volume
Today's trading volume
1.24M
Recent News
How Investors Are Reacting To Erasca (ERAS) Wider Losses And Early Oncology Pipeline Efficacy Signs
Erasca, Inc. recently reported first-quarter 2026 results showing a net loss of US$183.44 million, alongside expanded clinical progress for its oncology pipeline. Despite the larger loss, the company highlighted robust early efficacy and generally well-tolerated safety for ERAS-0015 and continued advancement of pan-KRAS candidate ERAS-4001, drawing positive commentary from JPMorgan. With ERAS-0015’s early efficacy profile in focus, we’ll now examine what these developments mean for Erasca’s...
Merck Broadens KEYTRUDA Collaborations As Patent Expiry Pressure Builds
Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data for INBRX-106 plus KEYTRUDA in head and neck cancer, with plans to move into Phase 3. These updates signal further external partnerships around KEYTRUDA combinations, adding to Merck's oncology pipeline as key patents approach expiry. For investors watching large pharma, Merck's focus on...
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the
JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels
Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026. The Fly reported on May 4 that JPMorgan is maintaining an Overweight rating on Erasca, Inc. (NASDAQ:ERAS) and recommends buying the stock at current levels. The firm believes that the stock boasts several catalysts over the coming months and believes […]
Erasca Weighs ERAS-0015 Trial Progress Against Legal And Valuation Questions
Erasca (NasdaqGS:ERAS) reported positive preliminary Phase 1 data for its pan RAS molecular glue candidate ERAS-0015 targeting RAS mutant cancers. The same asset is now at the center of an investigation into potential securities law violations related to patent infringement and trade secret allegations. Erasca's share price is currently $10.9, with the stock showing very large 1 year gains of around 7x and a 203.6% return year to date. The move has not been in a straight line, with a 36.3%...